Cardiomyopathy

According to the clinical practice guidelines, what is recommended for patients with cardiomyopathy and their relatives?

What is recommended for adolescents with cardiomyopathy regarding the transition of care from pediatric to adult services?

What is recommended for all patients with suspected or established cardiomyopathy according to the clinical practice guidelines?

What is recommended for all patients with suspected cardiomyopathy to aid in diagnosis, provide clues to underlying aetiology, determine inheritance pattern, and identify at-risk relatives?

According to the clinical practice guidelines, what is recommended for all patients with suspected or confirmed cardiomyopathy to evaluate aetiology, assess disease severity, and aid in detection of extracardiac manifestations and assessment of secondary organ dysfunction?

In the diagnosis of cardiomyopathies, when should additional (second-level) tests be considered?

In the initial evaluation and follow-up of patients with cardiomyopathy, what is recommended to monitor disease progression and aid in risk stratification and management?

In patients with cardiomyopathy, what is recommended at initial evaluation according to the clinical practice guidelines?

According to clinical practice guidelines, what is the recommendation for contrast-enhanced CMR in patients with cardiomyopathy during follow-up?

In patients with cardiac amyloidosis, AndersonFabry disease, sarcoidosis, inflammatory cardiomyopathies, and haemochromatosis with cardiac involvement, what imaging modality should be considered for serial follow-up and assessment of therapeutic response?

In families with cardiomyopathy in which a disease-causing variant has been identified, what imaging technique should be considered in genotype-positive/phenotype-negative family members to aid diagnosis and detect early disease?

In cases of familial cardiomyopathy without a genetic diagnosis, what imaging modality may be considered in phenotype-negative family members to aid diagnosis and detect early disease?

Which type of imaging is recommended for patients with suspected ATTR-related cardiac amyloidosis to aid in diagnosis?

In patients with suspected cardiomyopathy who have inadequate echocardiographic imaging and contraindications to CMR, which imaging modality should be considered?

In patients with suspected cardiomyopathy, what imaging modality should be considered to exclude congenital or acquired coronary artery disease as a cause of the observed myocardial abnormality?

Which diagnostic imaging technique should be considered for patients with cardiomyopathy when cardiac sarcoidosis is suspected?

In patients with suspected cardiomyopathy, when should EMB be considered to aid in diagnosis and management?

What is recommended for families with an inherited or suspected inherited cardiomyopathy, regardless of whether genetic testing is being considered?

What is recommended for the genetic testing of cardiomyopathy according to clinical practice guidelines?

According to clinical practice guidelines, what is recommended for individuals undergoing genetic testing for cardiomyopathy?

In the context of genetic counselling for cardiomyopathies, when is it recommended to perform prenatal diagnostic testing if pursued by the family?

According to clinical practice guidelines, what should be considered for all families with a genetic diagnosis in cardiomyopathies?

For which patients is genetic testing recommended in cases of cardiomyopathy according to the clinical practice guidelines?

In the context of genetic counselling and testing in cardiomyopathies, what is recommended for a deceased individual identified to have cardiomyopathy at post mortem?

In patients fulfilling diagnostic criteria for cardiomyopathy, genetic testing may be considered under which conditions?

In patients with a borderline phenotype not fulfilling diagnostic criteria for a cardiomyopathy, when may genetic testing be considered?

For adult at-risk relatives of individuals with a confirmed genetic diagnosis of cardiomyopathy, what is recommended regarding genetic testing?

When should cascade genetic testing with pre- and post-test counseling be considered in pediatric at-risk relatives in families with cardiomyopathy?

When should testing for the presence of a familial variant of unknown significance be considered in cardiomyopathies?

In the context of genetic counselling and testing for cardiomyopathies, what is the recommendation regarding diagnostic genetic testing for a phenotype-negative relative of a patient with cardiomyopathy?

What is the recommendation for orthotopic cardiac transplantation in eligible cardiomyopathy patients with advanced heart failure or intractable ventricular arrhythmia refractory to medical/invasive/device therapy?

In patients with cardiomyopathy and advanced heart failure (NYHA class III-IV) despite optimal pharmacological and device treatment, what therapy is recommended to improve symptoms and reduce the risk of heart failure hospitalization and premature death while awaiting a heart transplant?

In patients with advanced heart failure (NYHA class IIIIV) due to cardiomyopathy, who are not eligible for cardiac transplantation or other surgical options, and without severe right ventricular dysfunction, what is recommended to reduce the risk of death and improve symptoms?

What is recommended for all patients with hypertrophic cardiomyopathy (HCM) or cardiac amyloidosis and atrial fibrillation (AF) or atrial flutter to reduce the risk of stroke and thromboembolic events (unless contraindicated)?

In patients with cardiomyopathy and atrial fibrillation or atrial flutter, when is oral anticoagulation recommended to reduce the risk of stroke and thromboembolic events?

What is recommended to reduce the risk of stroke and thromboembolic events in patients with restrictive cardiomyopathy (RCM) and atrial fibrillation (AF) or atrial flutter, unless contraindicated?

In patients with DCM, NDLVC, or ARVC who have AF or atrial flutter, at what CHA2DS2-VASc score should oral anticoagulation be considered to reduce the risk of stroke and thromboembolic events in men and women, respectively?

In patients with cardiomyopathy and paroxysmal or persistent atrial fibrillation, what is recommended for rhythm control after one failed or intolerant class I or III antiarrhythmic drug to improve symptoms of AF recurrences?

In patients with cardiomyopathy and atrial fibrillation, what is recommended to reverse left ventricular (LV) dysfunction when a tachycardia-induced component is highly probable, regardless of their symptom status?

According to the clinical practice guidelines for the management of atrial fibrillation and atrial flutter in patients with cardiomyopathy, what is the recommended approach for maintaining sinus rhythm in patients without major risk factors for recurrence?

In the management of atrial fibrillation and atrial flutter in patients with cardiomyopathy, which therapy should be considered as first-line rhythm control to improve symptoms in selected patients with paroxysmal or persistent AF without major risk factors for recurrences, considering patient choice, benefit, and risk?

In patients with cardiomyopathy, atrial fibrillation (AF), and heart failure and/or reduced left ventricular ejection fraction (LVEF), what intervention should be considered to prevent AF recurrences and improve quality of life (QoL), LVEF, survival, and reduce heart failure hospitalization?

Which of the following is recommended to reduce atrial fibrillation (AF) burden and symptom severity in patients with cardiomyopathy?

In patients with cardiomyopathy, under what condition is the implantation of a cardioverter defibrillator recommended?

In patients with cardiomyopathy, what is recommended to guide ICD implantation?

Prior to ICD implantation, what should patients be counseled on?

In patients with cardiomyopathy, under what condition is it not recommended to implant an ICD?

In patients with HCM, DCM, and ARVC who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained ventricular arrhythmia causing syncope or hemodynamic compromise in the absence of reversible causes, what is the recommended intervention?

In patients with NDLVC and RCM who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained ventricular arrhythmia causing syncope or haemodynamic compromise in the absence of reversible causes, what is the recommended intervention?

In patients with cardiomyopathy presenting with haemodynamically tolerated ventricular tachycardia (VT) and in the absence of reversible causes, what is the recommended action according to clinical practice guidelines?

In patients with cardiomyopathy who have not suffered a previous cardiac arrest or sustained ventricular arrhythmia, when is comprehensive SCD risk stratification recommended?

In patients with hypertrophic cardiomyopathy (HCM), what is recommended for primary prevention?

In the context of primary prevention, in which conditions should an implantable cardioverter defibrillator be considered?

In patients with cardiomyopathy who require pacemaker implantation, what should be considered to evaluate the need for ICD implantation?

When an ICD is indicated in patients with cardiomyopathy, what is recommended to be evaluated?

In patients with cardiomyopathy who require an implantable cardioverter defibrillator (ICD) for primary prevention, when should subcutaneous defibrillators be considered as an alternative to transvenous defibrillators?

In the context of primary prevention, which patient group should consider using a wearable cardioverter defibrillator according to the guideline recommendation?

According to clinical practice guidelines, how often should clinically stable patients with cardiomyopathy undergo routine follow-up using a multiparametric approach that includes ECG and echocardiography?

In patients with cardiomyopathy, when is clinical evaluation with ECG and multimodality imaging recommended?

In the context of family screening and follow-up evaluation of relatives, what is recommended for first-degree relatives who have the same disease-causing variant as the proband following cascade genetic testing?

Following cascade genetic testing, what is recommended for first-degree relatives without a phenotype who do not have the same disease-causing variant as the proband?

When no P/LP variant is identified in the proband or genetic testing is not performed, what initial clinical evaluation is recommended for first-degree relatives?

When no P/LP variant is identified in the proband or genetic testing is not performed, what approach should be considered for the regular, long-term clinical evaluation of first-degree relatives?

During cascade screening, where a first- degree relative has died, who should be considered for clinical evaluation?

According to clinical practice guidelines, what is recommended for individuals who have experienced the premature sudden cardiac death of a family member with cardiomyopathy?

According to clinical practice guidelines, what is recommended for individuals with an inherited cardiomyopathy who receive an implantable cardioverter defibrillator?

According to clinical practice guidelines, what is recommended for psychological support in patients and family members with inherited cardiomyopathies?

In patients with HCM, what is recommended during initial evaluation to detect LVOTO?

In symptomatic patients with HCM and a resting or provoked peak instantaneous LV outflow tract gradient <50 mmHg, which diagnostic method is recommended to detect provocable LVOTO and exercise-induced mitral regurgitation?

In patients with HCM and LVOTO, under which circumstances should transesophageal echocardiography be considered?

In symptomatic patients with HCM and inconclusive non-invasive cardiac imaging, which procedure may be considered to assess the severity of LVOTO and measure LV filling pressures?

Which imaging modality may be considered before ASA or myectomy to assess the extent and distribution of hypertrophy and myocardial fibrosis in HCM?

According to clinical practice guidelines, what should be considered for patients with resting or provokable LVOTO?

Before considering invasive management of LVOTO in patients with new-onset or poorly controlled AF, what should be considered?

Which class of medication is recommended as first-line therapy to improve symptoms in patients with resting or provoked LVOTO?

In the management of symptomatic patients with resting or provoked LVOTO who are intolerant or have contraindications to beta-blockers, which medications are recommended to be titrated to the maximum tolerated dose to improve symptoms?

Which medication is recommended in addition to a beta-blocker to improve symptoms in patients with resting or provoked LVOTO, titrated to the maximum tolerated dose?

Which medication should be considered in addition to a beta-blocker (or, if not possible, with verapamil or diltiazem) to improve symptoms in adult patients with resting or provoked LVOTO, and titrated to maximum tolerated dose with echocardiographic surveillance of LVEF?

In the medical treatment of LVOTO, which medication, titrated to maximum tolerated dose with echocardiographic surveillance of LVEF, should be considered as monotherapy in symptomatic adult patients with resting or provoked LVOTO who are intolerant or have contraindications to beta-blockers, verapamil/diltiazem, or disopyramide?

In patients with severe provocable LVOTO presenting with hypotension and acute pulmonary oedema who do not respond to fluid administration, which treatment should be considered?

For patients with resting or provoked LVOTO who are intolerant to or have contraindications to beta-blockers and verapamil/diltiazem, which medication may be considered as monotherapy to improve symptoms?

Which of the following medications may be considered in selected cases in asymptomatic patients with resting or provoked LVOTO to reduce LV pressures?

For symptomatic LVOTO, what medical treatment may be considered to improve exertional dyspnea?

According to clinical practice guidelines, who should perform septal reduction therapy (SRT) for the management of hypertrophic cardiomyopathy (HCM)?

According to clinical practice guidelines, in which specific patient population is septal reduction therapy (SRT) recommended to improve symptoms?

In patients with an indication for septal reduction therapy (SRT), which procedure is recommended for children and adults with other lesions requiring surgical intervention (e.g., mitral valve abnormalities)?

Under which condition should septal reduction therapy (SRT) be considered in patients?

In which scenario should mitral valve repair or replacement be considered according to the guidelines for septal reduction therapy?

In patients with a resting or maximum provokedLVOTOgradient 50 mmHg and moderate- to- severe mitral regurgitation following isolated myectomy, what intervention should be considered?

In which patient scenario may septal reduction therapy (SRT) be considered according to the clinical practice guidelines?

In patients with a resting or maximum provoked LVOTO gradient 50 mmHg and moderate-to-severe mitral regurgitation following isolated myectomy, what is the recommended consideration according to clinical practice guidelines?

In patients with hypertrophic cardiomyopathy (HCM) and symptomatic atrial fibrillation (AF), which procedure(s) may be considered during septal myectomy?

In patients with resting or provokable LVOTO 50 mmHg, sinus rhythm, and drug-refractory symptoms, which treatment may be considered if they have contraindications for ASA or septal myectomy, or are at high risk of developing heart block following these procedures?

In patients with resting or provocable LVOTO 50 mmHg, sinus rhythm, and drug-refractory symptoms, who have an indication for an ICD, what type of device may be considered to reduce the LV outflow tract gradient or facilitate medical treatment with beta-blockers and/or verapamil?

Which medications should be considered to improve symptoms in patients with angina-like chest pain even in the absence of LVOTO or obstructive CAD?

In patients with angina-like chest pain and no obstructive CAD, what treatment may be considered if there is no LVOTO?

Which medication may be considered to improve symptoms in patients with angina-like chest pain even in the absence of LVOTO or obstructive CAD?

In patients with hypertrophic cardiomyopathy, which of the following is recommended for secondary prevention of sudden cardiac death?

In patients aged 16 years with hypertrophic cardiomyopathy, which tool is recommended for estimating the risk of sudden cardiac death at 5 years for primary prevention?

What method is recommended for estimating the risk of sudden death at 5 years in patients aged <16 years with hypertrophic cardiomyopathy for primary prevention?

In patients with hypertrophic cardiomyopathy, how often is it recommended that the 5-year risk of sudden cardiac death (SCD) be assessed?

Under what condition should implantation of an ICD be considered in patients with hypertrophic cardiomyopathy for primary prevention of sudden cardiac death?

In patients with LV apical aneurysms, what should decisions about primary prevention ICD be based on?

In patients with hypertrophic cardiomyopathy, under what conditions may implantation of an ICD be considered for primary prevention of sudden cardiac death (SCD)?

For patients with hypertrophic cardiomyopathy who are in the low-risk category (<4% estimated 5-year risk of SCD), what factor may be considered in shared decision-making with patients about prophylactic ICD implantation?

For patients with hypertrophic cardiomyopathy who are in the low-risk category (<4% estimated 5-year risk of sudden cardiac death), which factor may be considered in shared decision-making about prophylactic ICD implantation, despite the lack of robust data?

In patients with dilated cardiomyopathy (DCM) who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing hemodynamic instability, what is recommended to reduce the risk of sudden death and all-cause mortality?

In patients with dilated cardiomyopathy (DCM), symptomatic heart failure, and left ventricular ejection fraction (LVEF) 35% despite more than 3 months of optimal medical therapy (OMT), what is the recommended intervention to reduce the risk of sudden death and all-cause mortality?

Which factor should be considered in the estimation of sudden cardiac death (SCD) risk in patients with dilated cardiomyopathy (DCM) for primary prevention?

In patients with dilated cardiomyopathy (DCM) and a genotype associated with high sudden cardiac death (SCD) risk, what additional condition would justify considering an implantable cardioverter defibrillator (ICD) for primary prevention?

In patients with dilated cardiomyopathy (DCM), under which condition may an implantable cardioverter defibrillator (ICD) be considered for primary prevention?

In patients with dilated cardiomyopathy (DCM) without a genotype associated with high sudden cardiac death (SCD) risk and left ventricular ejection fraction (LVEF) >35%, under what conditions may an implantable cardioverter defibrillator (ICD) be considered?

How often is ambulatory ECG monitoring recommended in patients with NDLVC according to the clinical practice guidelines?

What is the recommended use of an ICD in patients with NDLVC for secondary prevention?

In patients with NDLVC, heart failure symptoms, and LVEF 35% despite >3 months of OMT, what intervention should be considered to reduce the risk of sudden death and all-cause mortality?

Based on the clinical practice guidelines, which factor should be considered in estimating SCD risk in patients with NDLVC?

In patients with NDLVC, when should an ICD be considered for primary prevention?

In patients with non-dilated left ventricular cardiomyopathy (NDLVC) and a genotype associated with high sudden cardiac death (SCD) risk, under what conditions may an implantable cardioverter defibrillator (ICD) be considered for primary prevention?

In patients with NDLVC without a genotype associated with high SCD risk and LVEF >35%, when may an ICD be considered?

According to the clinical practice guidelines, what is recommended for patients with ARVC to aid in diagnosis, management, and risk stratification?

Which therapy is recommended for ARVC patients with VE, NSVT, and VT?

In patients with ARVC, what medication should be considered when regular beta-blocker therapy fails to control arrhythmia-related symptoms?

In the management of patients with ARVC, what treatment should be considered when single-agent treatment has failed to control arrhythmia-related symptoms?

For patients with ARVC who have incessant VT or frequent appropriate ICD interventions for VT despite pharmacological therapy with beta-blockers, what should be considered for antiarrhythmic management?

What is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac arrest or recovered from a ventricular arrhythmia causing hemodynamic instability?

In patients with ARVC who have suffered a haemodynamically tolerated VT, what is recommended for secondary prevention?

In patients with ARVC, what should be considered to aid individualized decision-making for ICD implantation in primary prevention?

What tool should be considered to aid individualized decision-making for ICD implantation in patients with ARVC according to the updated guidelines?

Which of the following is recommended for differentiating RCM from HCM or DCM with restrictive physiology?

According to the clinical practice guidelines for the management of patients with RCM, what baseline investigations are recommended to be performed?

In managing patients with RCM, how often is cardiac catheterization recommended to measure pulmonary artery pressures and PVR in children?

According to clinical practice guidelines, what is recommended to reduce the risk of sudden death and all-cause mortality in patients with restrictive cardiomyopathy (RCM) who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing hemodynamic instability?

In the management of patients with RCM, what diagnostic procedure should be considered to exclude specific diagnoses such as iron overload, storage disorders, mitochondrial cytopathies, amyloidosis, and granulomatous myocardial diseases, and to diagnose restrictive myofibrillar disease caused by desmin variants?

In the management of children with Restrictive Cardiomyopathy (RCM), under what conditions may ICD implantation be considered?

What is the recommended type and intensity of exercise for all able individuals with cardiomyopathy?

What is recommended for exercise prescription in all patients with cardiomyopathy?

In genotype-positive/ phenotype-negative individuals with HCM, what is the recommendation regarding high-intensity exercise and competitive sports?

According to clinical practice guidelines, in which group of patients with hypertrophic cardiomyopathy (HCM) may high-intensity exercise and competitive sport be considered?

Which of the following exercise recommendations is appropriate for high-risk individuals with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction or exercise-induced complex ventricular arrhythmias?

According to clinical practice guidelines, what is recommended for genotype-positive/phenotype-negative individuals in families with ARVC concerning high-intensity exercise?

What type of exercise is not recommended for individuals with ARVC?

Which of the following exercise recommendations is advised for individuals who are gene positive and phenotype-negative for DCM and NDLVC, excluding those with pathogenic variants in LMNA and TMEM43?

Under which conditions may high-intensity exercise and competitive sport be considered for individuals with dilated cardiomyopathy (DCM) and non-dilated left ventricular cardiomyopathy (NDLVC)?

According to the clinical practice guidelines, under what condition may moderate-intensity exercise be considered for asymptomatic and optimally treated individuals with a left ventricular ejection fraction of 4049%?

According to clinical practice guidelines, which of the following statements is true regarding high-intensity exercise recommendations for patients with dilated cardiomyopathy (DCM) and non-dilated left ventricular cardiomyopathy (NDLVC)?

What is recommended for all women with cardiomyopathy regarding pre-pregnancy risk assessment and counseling?

In patients with cardiomyopathy, what is recommended for all women of fertile age and their partners?

According to clinical practice guidelines, what is recommended for all men and women with cardiomyopathy before conception?

In women with cardiomyopathies, under which conditions is vaginal delivery NOT recommended?

In patients with cardiomyopathy, what is recommended regarding medication management in advance of pregnancy?

According to clinical practice guidelines, which therapeutic approach is recommended for patients with cardiomyopathy and atrial fibrillation (AF) based on the stage of pregnancy?

In patients with cardiomyopathies, what is the recommendation regarding the continuation of beta-blockers during pregnancy?

In patients with peripartum cardiomyopathy, what should be considered according to the clinical practice guidelines?

What is recommended for all patients with cardiomyopathy undergoing surgery according to clinical practice guidelines?

In patients with cardiomyopathy and suspected or known heart failure scheduled for intermediate or high-risk non-cardiac surgery, which of the following is recommended for re-evaluation?

In patients with cardiomyopathy, which group should be referred for additional specialized investigations to a cardiomyopathy unit before undergoing elective non-cardiac surgery?

For patients under 65 years of age with a first-degree relative with cardiomyopathy, what is recommended before non-cardiac surgery (NCS) regardless of symptoms?

What is recommended as an integral part of the management of cardiomyopathy patients?